Celcuity Inc. (CELC) Stock
CELC has an Alpha Score of 4 out of 100 (poor), computed on Nov 2, 2026 from 2 of 4 sub-scores. 1 member of Congress disclosed 4 trades in CELC since 2020: 3 purchases and 1 sale, most recently Tom Malinowski (sale, May 26, 2021). 3 of the hedge funds AlphaScala tracks reported CELC in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Point72's at $68.10M.
What is CELC's Alpha Score?
How it works →Alpha Score of 4 reflects poor overall profile with poor momentum, poor quality. Based on 2 of 4 signals – score is capped at 75 until remaining data ingests.
Computed from 2 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 2, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded Celcuity Inc. (CELC)?
Most recent: Tom Malinowski (sale, May 26, 2021); records start Jun 18, 2020.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Tom Malinowski D-NJ · House | 2021-05-26 | sale | $1k – $15k |
| Tom Malinowski D-NJ · House | 2020-06-23 | purchase | $1k – $15k |
| Tom Malinowski D-NJ · House | 2020-06-22 | purchase | $1k – $15k |
| Tom Malinowski D-NJ · House | 2020-06-18 | purchase | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 5, 2026.
See all CELC political trades →Which hedge funds own CELC?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Point72 Steve Cohen | 651K | $68.10M | +132% |
| Marshall Wace | 182K | $19.06M | +864% |
| D.E. Shaw David Shaw | 30K | $3.18M | +47% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Celcuity Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Mar 31, 26 | Buller Richard E | Director | SELL | 2.3K | $256K |
| Mar 31, 26 | Buller Richard E | Director | SELL | 675 | $75K |
| Jan 27, 26 | Dalvey David | Director | SELL | 20.0K | $2.4M |
| Dec 5, 25 | Buller Richard E | Director | SELL | 1.5K | $157K |
| Dec 5, 25 | Buller Richard E | Director | SELL | 1.5K | $160K |
| Dec 1, 25 | Buller Richard E | Director | SELL | 1.1K | $108K |
| Nov 21, 25 | Dalvey David | Director | SELL | 15.0K | $1.5M |
| Nov 20, 25 | Buller Richard E | Director | SELL | 3.9K | $377K |
SEC Form 4 filings as of Nov 5, 2026
See cluster-buy signals across all tickers →What are CELC's key statistics?
Key statistics as of Nov 2, 2026
CELC price chart
Powered by TradingViewWhat does Celcuity Inc. do?
Celcuity Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for solid tumors. Its primary objective is to address dysregulated oncogenic signaling by inhibiting pathways that drive tumor growth and resistance. The company’s lead therapeutic candidate, gedatolisib, is a potent pan-PI3K and mTORC1/2 inhibitor designed to comprehensively block the PI3K/AKT/mTOR pathway, a central node in cancer proliferation and survival. Celcuity is advancing multiple late-stage studies, including Phase 3 programs in hormone receptor–positive, HER2-negative advanced breast cancer and additional trials exploring combinations across tumor types. The firm’s platform aims to identify previously undetectable cancer drivers, aligning drug development with tumor biology to improve therapeutic precision. Within the biopharmaceutical market, Celcuity contributes to the growing field of pathway-centric oncology, where rational combinations and biomarker-informed strategies seek to enhance clinical benefit and address unmet needs in metastatic settings. This focus positions the company as a participant in the evolution of precision oncology, emphasizing mechanism-driven development and rigorous clinical evaluation.